Neuropathology of depression in Alzheimer's disease: Current knowledge and the potential for new treatments

Ahmad A. Khundakar, Alan J. Thomas

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Depression is among the most common behavioral and psychological symptoms of dementia, and leads to more rapid decline and higher mortality. Treatment for depression in dementia has centered on conventional antidepressant drug treatment based around the monoamine hypothesis of depression. However, recent major studies have suggested that conventional antidepressant treatments that aim to correct underlying deficits in monoamine neurotransmitters are not effective for depression in dementia. Postmortem studies have also suggested that depression in dementia does not arise from serotonergic or noradrenergic abnormalities, or indeed from the degenerative pathology associated with Alzheimer's disease. In contrast, considerable recent evidence has suggested that alterations in glutamatergic transmission may contribute to the pathophysiology of depression. This supports the view that treatment-resistant depressed patients, such as many dementia patients, may benefit from agents affecting glutamate transmission. This review will thus draw together the wealth of pathological data examining the basis of depression in Alzheimer's disease and relate this to current thinking on treatment, with the aim of generating discussion on potential novel therapeutic strategies.

Original languageEnglish
Pages (from-to)27-41
Number of pages15
JournalJournal of Alzheimer's Disease
Volume44
Issue number1
DOIs
Publication statusPublished - 1 Jan 2015

Fingerprint

Alzheimer Disease
Depression
Dementia
Therapeutics
Antidepressive Agents
Excitatory Amino Acid Agents
Behavioral Symptoms
Neuropathology
Neurotransmitter Agents
Pathology
Psychology
Mortality

Cite this

@article{da3bcee144f140cbbf02b846ece7b046,
title = "Neuropathology of depression in Alzheimer's disease: Current knowledge and the potential for new treatments",
abstract = "Depression is among the most common behavioral and psychological symptoms of dementia, and leads to more rapid decline and higher mortality. Treatment for depression in dementia has centered on conventional antidepressant drug treatment based around the monoamine hypothesis of depression. However, recent major studies have suggested that conventional antidepressant treatments that aim to correct underlying deficits in monoamine neurotransmitters are not effective for depression in dementia. Postmortem studies have also suggested that depression in dementia does not arise from serotonergic or noradrenergic abnormalities, or indeed from the degenerative pathology associated with Alzheimer's disease. In contrast, considerable recent evidence has suggested that alterations in glutamatergic transmission may contribute to the pathophysiology of depression. This supports the view that treatment-resistant depressed patients, such as many dementia patients, may benefit from agents affecting glutamate transmission. This review will thus draw together the wealth of pathological data examining the basis of depression in Alzheimer's disease and relate this to current thinking on treatment, with the aim of generating discussion on potential novel therapeutic strategies.",
author = "Khundakar, {Ahmad A.} and Thomas, {Alan J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.3233/JAD-148003",
language = "English",
volume = "44",
pages = "27--41",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "1",

}

Neuropathology of depression in Alzheimer's disease : Current knowledge and the potential for new treatments. / Khundakar, Ahmad A.; Thomas, Alan J.

In: Journal of Alzheimer's Disease, Vol. 44, No. 1, 01.01.2015, p. 27-41.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Neuropathology of depression in Alzheimer's disease

T2 - Current knowledge and the potential for new treatments

AU - Khundakar, Ahmad A.

AU - Thomas, Alan J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Depression is among the most common behavioral and psychological symptoms of dementia, and leads to more rapid decline and higher mortality. Treatment for depression in dementia has centered on conventional antidepressant drug treatment based around the monoamine hypothesis of depression. However, recent major studies have suggested that conventional antidepressant treatments that aim to correct underlying deficits in monoamine neurotransmitters are not effective for depression in dementia. Postmortem studies have also suggested that depression in dementia does not arise from serotonergic or noradrenergic abnormalities, or indeed from the degenerative pathology associated with Alzheimer's disease. In contrast, considerable recent evidence has suggested that alterations in glutamatergic transmission may contribute to the pathophysiology of depression. This supports the view that treatment-resistant depressed patients, such as many dementia patients, may benefit from agents affecting glutamate transmission. This review will thus draw together the wealth of pathological data examining the basis of depression in Alzheimer's disease and relate this to current thinking on treatment, with the aim of generating discussion on potential novel therapeutic strategies.

AB - Depression is among the most common behavioral and psychological symptoms of dementia, and leads to more rapid decline and higher mortality. Treatment for depression in dementia has centered on conventional antidepressant drug treatment based around the monoamine hypothesis of depression. However, recent major studies have suggested that conventional antidepressant treatments that aim to correct underlying deficits in monoamine neurotransmitters are not effective for depression in dementia. Postmortem studies have also suggested that depression in dementia does not arise from serotonergic or noradrenergic abnormalities, or indeed from the degenerative pathology associated with Alzheimer's disease. In contrast, considerable recent evidence has suggested that alterations in glutamatergic transmission may contribute to the pathophysiology of depression. This supports the view that treatment-resistant depressed patients, such as many dementia patients, may benefit from agents affecting glutamate transmission. This review will thus draw together the wealth of pathological data examining the basis of depression in Alzheimer's disease and relate this to current thinking on treatment, with the aim of generating discussion on potential novel therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=84920830713&partnerID=8YFLogxK

U2 - 10.3233/JAD-148003

DO - 10.3233/JAD-148003

M3 - Review article

C2 - 25208623

AN - SCOPUS:84920830713

VL - 44

SP - 27

EP - 41

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 1

ER -